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Background: Guidelines recommend that symptoms as well as lung function should be monitored for the
management of patients with chronic obstructive pulmonary disease (COPD). However, limited data are available
regarding the longitudinal change in dyspnea, and it remains unknown which of relevant measurements might be
used for following dyspnea.
Methods: We previously consecutively recruited 137 male outpatients with moderate to very severe COPD, and
followed them every 6 months for 5 years. We then reviewed and reanalyzed the data focusing on the relationships
between the change in dyspnea and the changes in other clinical measurements of lung function, exercise
tolerance tests and psychological status. Dyspnea with activities of daily living was assessed with the Oxygen Cost
Diagram (OCD) and modified Medical Research Council dyspnea scale (mMRC), and two dimensions of
disease-specific health status questionnaires of the Chronic Respiratory Disease Questionnaire (CRQ) and the
St. George’s Respiratory Questionnaire (SGRQ) were also used. Dyspnea at the end of exercise tolerance tests was
measured using the Borg scale.
Results: The mMRC, CRQ dyspnea and SGRQ activity significantly worsened over time (p < 0.001), but the OCD did
not (p = 0.097). Multiple regression analyses revealed that the changes in the OCD, mMRC, CRQ dyspnea and SGRQ
activity were significantly correlated to changes in forced expiratory volume in one second (FEV1) (correlation of
determination (r2) = 0.05-0.19), diffusing capacity for carbon monoxide (r2 = 0.04-0.08) and psychological status
evaluated by Hospital Anxiety and Depression Scale (r2 = 0.14-0.17), although these correlations were weak.
Peak Borg score decreased rather significantly, but was unrelated to changes in clinical measurements.
Conclusion: Dyspnea worsened over time in patients with COPD. However, as different dyspnea measurements
showed different evaluative characteristics, it is important to follow dyspnea using appropriate measurements.
Progressive dyspnea was related not only to progressive airflow limitation, but also to various factors such as
worsening of diffusing capacity or psychological status. Changes in peak dyspnea at the end of exercise may
evaluate different aspects from other dyspnea measurements.
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Dyspnea is the main symptom of which most patients
with chronic obstructive pulmonary disease (COPD)
complain. Guidelines recommend that symptoms as well
as lung function should be monitored for the manage-
ment of patients with COPD [1]. Dyspnea is regarded as
a potential marker of disease progression of COPD, be-
cause it worsens over time, predicts mortality, and
responds to therapy [2]. However, only a few observa-
tional studies have been performed to analyze the longi-
tudinal changes in dyspnea [3-5]. It is still unknown how
changes in dyspnea are related to changes in forced ex-
piratory volume in one second (FEV1) and other clinical
measurements; the gold standard measurement for fol-
lowing dyspnea has also not been established, as none of
the available methods is optimal, having regard to their
merits and limitations [6].
In previous cross-sectional studies, we reported that
three dyspnea measurements with activities of daily living
such as the Oxygen Cost Diagram (OCD) [7], the modi-
fied Medical Research Council dyspnea scale (mMRC) [8]
and the Baseline Dyspnea Index (BDI) [9], and the two
dimensions of disease-specific health status questionnaires
of the Chronic Respiratory Disease Questionnaire (CRQ)
[10] and the St. George’s Respiratory Questionnaire
(SGRQ) [11] performed equally well in assessing dyspnea
of patients with COPD; however, the Borg scale [12] at
the end of exercise evaluated different aspects of dyspnea
[13]. However, although unidimensional measurements
such as OCD or MRC, which were initially developed to
quantify dyspnea in a category or analog scale, have excel-
lent discriminative properties, it is estimated that they
would not be so useful as an evaluative instrument [14].
Therefore, we hypothesized that, although different dys-
pnea measurements worsened over time, the associated
changes would differ depending on the instruments used,
and that changes in dyspnea are related to the changes in
a variety of factors, such as FEV1. We previously recruited
patients with COPD, and assessed multiple clinical mea-
surements every 6 months over 5 years [5,15]. In the
present study, we reviewed the data and compared longi-
tudinal changes in different dyspnea measurements and
the relevant contributory factors using multiple regression
analyses.
Methods
Subjects
We previously consecutively recruited 137 male outpati-
ents with moderate to very severe COPD [5,15]. Inclu-
sion criteria included: (1) smoking history of more than
20 pack years; (2) maximal FEV1/forced vital capacity of
less than 0.7 and postbronchodilator FEV1 of less than
80% of the predicted normal; (3) regular attendance over
6 months; (4) no COPD exacerbations over thepreceding 6 weeks; and (5) no uncontrolled comorbid-
ities. Patient clinical measurements including smoking
status, physiological measurements and patient reported
measurements were evaluated at entry and thereafter
every 6 months over 5 years. When a COPD exacerba-
tion requiring a change in treatment occurred within
4 weeks of a reassessment day, the reevaluation was
postponed for at least 4 weeks until the patient recov-
ered. The study protocol was approved by the institu-
tional ethical committee of Kyoto University.
Physiological measurements
Pulmonary function tests were performed at least
12 hours after the withdrawal of inhaled bronchodilators
[5,15]. Subjects underwent spirometry using a spirom-
eter (AUTOSPIRO AS-600, Minato Medical Science Co.
Ltd., Osaka, Japan) before and at 15 and 60 min after in-
haling salbutamol (400 μg) and ipratropium bromide
(80 μg). Spirometry was performed three times, and the
highest values recorded were analyzed. Functional re-
sidual capacity (FRC) was measured by the closed-circuit
helium method, and diffusing capacity for carbon mon-
oxide (DLCO) was measured by the single-breath tech-
nique (CHESTAC-65V, Chest, Tokyo, Japan).
Exercise tests were performed 60 min after the inhal-
ation of bronchodilators, using symptom-limited pro-
gressive cycle ergometry [5,15,16]. Exercise data were
recorded using an automated exercise testing system
which converts the breath-by-breath analog input into a
digital form on-line. Minute ventilation (V˙Е) and oxygen
tension in the expired air were determined every eight
breaths, and mean V˙Е, oxygen uptake (V˙О2) and carbon
dioxide production were then calculated. Their peak
values were the highest levels reached during exercise.
Dyspnea was scored at the end of exercise using the
Borg scale (0–10) [12].
Patient reported measurements
To assess dyspnea during activities of daily living, the
Japanese versions of the OCD [7,13] and the mMRC
(version 1) [8,13] were used. The OCD is a visual
analogue scale corresponding to oxygen requirements at
different activity levels, which is represented as a value
ranging from 0 to 100. mMRC is a 5-point scale (0–4)
based on degrees of various physical activities that pre-
cipitate dyspnea. Less dyspnea is indicated by higher
scores on the OCD, and lower scores on the mMRC.
Additionally, as a specific heath status dimension for
evaluating dyspnea, the dyspnea domain of the CRQ
[10,13] and the activity component of the SGRQ [11,13]
were also used. Although the original CRQ version was
interview-administrated, the CRQ was self-administered
without informed administration in the present study.
For the CRQ dyspnea, each patient defined the five
Table 1 Baseline data and annual changes in 137 patients
with COPD
Baseline Annual change P value
Age (years) 69.0 ± 0.6
Smoking (current/former) 34/103
Body mass index (kg/m2) 21.2 ± 0.3 -0.14 ± 0.04 0.0013
Resting physiological measurements
FEV1 (l) 1.22 ± 0.04 -0.0254 ± 0.0059 <0.001
FEV1 (%predicted) 45.9 ± 1.3 -0.9 ± 0.2 <0.001
FRC (%predicted) 110.0 ± 2.2 1.9 ± 0.4 <0.001
DLCO (%predicted) 64.6 ± 1.8 -3.5 ± 0.4 <0.001
Peak exercise measurements
Peak V˙О2 (ml/min/kg) 14.8 ± 0.3 -0.5 ± 0.1 <0.001
Peak V˙Е (l/min) 40 ± 1 -2.5 ± 0.2 <0.001
Peak VТ (%predicted VC) 37.8 ± 0.7 -2.2 ± 0.2 <0.001
Dyspnea measurements
OCD (0-100) 60 ± 2 -0.6 ± 0.3 0.097
mMRC (0–4) 1.1 ± 0.1 0.14 ± 0.02 <0.001
CRQ dyspnea (1–7) 5.28 ± 0.09 -0.10 ± 0.02 <0.001
SGRQ activity (0–100) 43.1 ± 1.8 1.83 ± 0.39 <0.001
Borg score at the end
of exercise (0–10)
6.4 ± 0.1 -0.13 ± 0.03 <0.001
Psychological status measurements
HADS anxiety (0–21) 4.7 ± 0.3 0.16 ± 0.08 0.046
HADS depression (0–21) 3.9 ± 0.3 0.17 ± 0.07 0.023
Data presented as means ± SE or number. FEV1 forced expiratory volume in
one second; FRC functional residual capacity, DLCO diffusing capacity for
carbon monoxide, _VO2 oxygen uptake, _VE minute ventilation, VT tidal volume,
VC vital capacity, OCD Oxygen Cost Diagram, mMRC modified Medical
Research Council dyspnea scale, CRQ Chronic Respiratory Disease
Questionnaire, SGRQ St. George’s Respiratory Questionnaire, HADS Hospital
Anxiety and Depression Scale.
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disease. Each item was scored on a 7-point scale, and
the score was calculated as a mean of the sum. The
SGRQ activity includes 16 items, and its scores range
from 0 to 100. Better health is indicated by higher scores
on the CRQ, and lower scores on the SGRQ.
Psychological status was evaluated using the Japanese
version of the Hospital Anxiety and Depression Scale
(HADS) [13,17], which consists of 14 items, 7 for anxiety
and 7 for depression. Each item is scored from 0 to 3,
where a score of 3 represents a state of the worst anxiety
or depression. The sum of these items produces 2 sub-
scales ranging from 0 to 21.
Follow-up data
Among the 137 patients, 72 patients attended the last 5-
year evaluation, and only one patient was unavailable for
follow-up [5]. Twenty-five patients died during the 5-
year period, 36 patients dropped out of the study due to
an inability to attend the hospital for various reasons,
and 3 patients skipped the last appointment.
Statistical analysis
Results are expressed as means ± SE. Mixed effects
models for the slopes were used to estimate longitudinal
changes in the clinical parameters [5,15,18,19] using
Statistical Analysis System PROC MIXED software. In
the analyses, the covariates included age and smoking
status as fixed effects, whereas time was entered as a
random effect [5,15]. Relationships between the slope
changes in dyspnea measurements and other clinical
measurements were analyzed by Pearson’s correlation
coefficient tests. Stepwise multiple regression analyses
were used to identify those variables that could best pre-
dict the changes in dyspnea measurements. Simple linear
regression analyses were performed to predict the
changes in dyspnea measurements from the changes in
FEV1. A p value of less than 0.05 was considered to indi-
cate statistical significance, except for a p value of less
than 0.01 in the case of the relationships between the
slope changes.
Results
Baseline characteristics and the annual changes in clin-
ical measurements of the 137 male outpatients are
shown in Table 1 and elsewhere [5,15]. Body mass index
(BMI) significantly fell (p = 0.0013). The annual decline
in postbronchodilator FEV1 was −25.4 ± 5.9 ml/year
(p < 0.001), which was compatible with recent observa-
tional studies [20-22]. DLCO significantly declined
(p < 0.001), and FRC increased (p < 0.001).
Regarding dyspnea measurements, the mMRC, CRQ
dyspnea and SGRQ activity significantly worsened
(p< 0.001), but the change in the OCD was not significant(p= 0.097) (Table 1). Borg score at the end of exercise ra-
ther significantly improved (p< 0.001). Regarding other
clinical measurements, peak exercise measurements of
V˙О2, V˙Е and tidal volume (VТ) significantly declined
(p< 0.001) and psychological status assessed by the HADS
significantly worsened (p < 0.05).
Table 2 shows the inter-relationships between the
changes in different dyspnea measurements. The changes
in the OCD, mMRC, CRQ dyspnea and SGRQ activity
were significantly moderately inter-correlated with each
other (correlation coefficient (r) = 0.45-0.52, p < 0.001).
The change in the Borg score was unrelated to the
changes in other dyspnea measurements.
Table 3 shows the relationships of the changes in dif-
ferent dyspnea measurements to the changes in clinical
measurements. Among dyspnea measurements, only the
change in the CRQ dyspnea was significantly correlated
with the change in BMI. The changes in the OCD,
mMRC, CRQ dyspnea and SGRQ activity were signifi-
cantly correlated with the changes in FEV1 (r = 0.29-0.49,
p < 0.001) and DLCO (r = 0.27-0.35, p < 0.01). These were
Table 2 Correlation coefficients between the changes in different dyspnea measurements
OCD (/year) mMRC (/year) CRQ dyspnea (/year) SGRQ activity (/year) Borg score (/year)
OCD (/year) 1
mMRC (/year) -0.51* 1
CRQ dyspnea (/year) 0.45* -0.49* 1
SGRQ activity (/year) -0.52* 0.52* -0.52* 1
Borg score (/year) -0.06 0.04 -0.10 0.02 1
* p < 0.001. OCD Oxygen Cost Diagram, mMRC modified Medical Research Council dyspnea scale, CRQ Chronic Respiratory Disease Questionnaire, SGRQ St.
George’s Respiratory Questionnaire.
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exercise measurements such as V˙Е (r = 0.22-0.30,
p < 0.01). The changes in the OCD, mMRC, CRQ dys-
pnea and SGRQ activity were all significantly correlated
to the changes in psychological status by the HADS
(r = 0.33-0.46, p < 0.001). The change in the Borg score at
the end of exercise was unrelated to any of the changes
in clinical variables.
Table 4 shows the results of the stepwise multiple re-
gression analyses to best predict the changes in dyspnea
measurements from the OCD, mMRC, CRQ dyspnea
and SGRQ activity using the factors significantly corre-
lated in Table 3 as explanatory variables. The changes in
FEV1 and DLCO accounted for a significant amount of
the variance (correlation of determination (r2) = 0.05-
0.19, and r2 = 0.04-0.08, respectively), as did the changes
in the HADS anxiety or depression (r2 = 0.14-0.17). The
change in the peak V˙О2 was significantly correlated with
the change in the mMRC (r2 = 0.07).
Figure 1 shows the relationships between the changes
in dyspnea and the change in FEV1. Although significant
relationships were observed between the change in dys-
pnea and the change in FEV1, patients showed variableTable 3 Correlation coefficients between the changes in dysp
OCD (/year) mMRC (/year) CR
Body mass index (kg/m2/year) 0.10 -0.16
Resting physiological measurements
FEV1 (ml/year) 0.30* -0.35*
FEV1 (%predicted/year) 0.29* -0.37*
FRC (%predicted/year) 0.08 -0.03
DLCO (%predicted/year) 0.27* -0.35*
Peak exercise measurements
Peak V˙О2 (ml/min/kg/year) 0.25* -0.35*
Peak V˙Е (l/min/year) 0.27* -0.30*
Peak VТ (%predicted VC/year) 0.14 -0.26*
Psychological status measurements
HADS anxiety (/year) -0.36* 0.36*
HADS depression (/year) -0.45* 0.46*
* p < 0.01. FEV1 forced expiratory volume in one second; FRC functional residual cap
minute ventilation, VT tidal volume, VC vital capacity, HADS Hospital Anxiety and D
Council dyspnea scale, CRQ Chronic Respiratory Disease Questionnaire, SGRQ St. Gechanges in dyspnea scores. Table 5 shows the results of
the regression analyses. Regarding the changes in (B)
mMRC, (C) CRQ dyspnea and (D) SGRQ activity, inter-
cepts of regression lines were shifted significantly toward
a worsening in dyspnea, respectively (p < 0.001).
Discussion
We have shown that: 1) the mMRC, CRQ dyspnea and
SGRQ activity significantly worsened over time, but not
the OCD; 2) these changes were significantly correlated to
the changes in various measurements such as FEV1, DLCO
and the HADS in multiple regression analyses; and 3)
peak Borg score during exercise decreased over time, indi-
cating that patients experienced significantly less breath-
lessness at the end of exercise, and this change was
unrelated to the changes in clinical measurements.
Regarding the OCD, mMRC, CRQ dyspnea and SGRQ
activity, although these exhibited similarly excellent dis-
criminative properties [13], the present study indicated
that the evaluative property of the OCD was inferior to
that of other measurements. As unidimensional scales
like the OCD and MRC detect the threshold of activities
that produce physical limitations caused by dyspnea,nea and the changes in clinical variables
Q dyspnea (/year) SGRQ activity (/year) Borg score (/year)
0.28* -0.19 0.14
0.36* -0.47* -0.08
0.37* -0.49* -0.10
-0.18 -0.10 0.11
0.32* -0.27* 0.03
0.16 -0.21 0.07
0.22* -0.24* 0.08
0.21 -0.30* 0.05
-0.33* 0.41* -0.00
-0.45* 0.43* 0.07
acity, DLCO diffusing capacity for carbon monoxide, _VO2 oxygen uptake, _VE
epression Scale, OCD Oxygen Cost Diagram, mMRC modified Medical Research
orge’s Respiratory Questionnaire.
Table 4 Results of stepwise regression analyses to best predict the changes in dyspnea
OCD (/year) mMRC (/year) CRQ dyspnea (/year) SGRQ activity (/year)
Body mass index (kg/m2/year) -
FEV1 (ml/year) 0.05 0.06 0.08 0.19
DLCO (%predicted/year) 0.05 0.08 0.07 0.04
Peak V˙О2 (ml/min/kg/year) - 0.07
Peak V˙Е (l/min/year) - - - -
Peak VТ (%predicted VC/year) - -
HADS anxiety (/year) - - - 0.14
HADS depression (/year) 0.17 0.17 0.16 -
Cumulative r2 0.27 0.38 0.32 0.37
Values indicate correlation of determination (r2). Missing values (-) indicate that independent variables were not statistically significant. FEV1 forced expiratory
volume in one second; FRC functional residual capacity, DLCO diffusing capacity for carbon monoxide, _VO2 oxygen uptake, _VE minute ventilation, VT tidal volume,
VC vital capacity, HADS Hospital Anxiety and Depression Scale, OCD Oxygen Cost Diagram, mMRC modified Medical Research Council dyspnea scale, CRQ Chronic
Respiratory Disease Questionnaire, SGRQ St. George’s Respiratory Questionnaire.
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satisfactory evaluative instruments [14]. Although the
mMRC showed statistically significant changes, the
mean change of 0.14 /year dose not reach even one
grade over 5 years. The guideline recommends the MRC
for dyspnea measurement in COPD for its simplicityFigure 1 Correlation of the annual change in FEV1 with the annual ch
dyspnea, and (D) SGRQ activity. Positive changes in OCD and CRQ dyspn
negative changes in mMRC and SGRQ activity.and excellent discriminative and predictive properties
[1,13,23]. However, the MRC with only 5 grades may be
too broad to longitudinally detect changes in dyspnea
for individuals, as other studies indicated that a multidi-
mensional dyspnea assessment such as the Transition
Dyspnea Index (TDI) [9] was superior to the MRC inanges in dyspnea measurements of (A) OCD, (B) mMRC, (C) CRQ
ea scores indicate better dyspneic status, which are indicated by
Table 5 Results of linear regression analysis to predict
the changes in dyspnea
Coefficient SE 95% CI P value
(A) Change in OCD (/year)
Intercept -0.17 0.14 -0.45-0.12 0.25
Change in FEV1 (ml/year) 15.9 4.4 7.2-24.5 <0.001
(B) Change in mMRC (/year)
Intercept 0.10 0.01 0.08-0.13 <0.001
Change in FEV1 (ml/year) -1.55 0.35 -2.25-0.85 <0.001
(C) Change in CRQ dyspnea (/year)
Intercept -0.07 0.01 -0.09-0.05 <0.001
Change in FEV1 (ml/year) 1.17 0.26 0.66-1.68 <0.001
(D) Change in SGRQ activity (/year)
Intercept 0.81 0.21 0.39-1.23 <0.001
Change in FEV1 (ml/year) -40.3 6.5 -53.1-27.5 <0.001
CI confidence interval, FEV1 forced expiratory volume in one second, OCD
Oxygen Cost Diagram, mMRC modified Medical Research Council dyspnea
scale, CRQ Chronic Respiratory Disease Questionnaire, SGRQ St. George’s
Respiratory Questionnaire.
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sional dyspnea measurements may be preferred for lon-
gitudinal follow-ups.
When comparing between the CRQ dyspnea and
SGRQ activity, considering the minimum clinically im-
portant difference (MCID) of 0.5 on the CRQ dyspnea
[25] and 4 on the SGRQ [26], the SGRQ activity
appeared to reach the MCID more rapidly than the CRQ
dyspnea. This may be because the former incorporates
more items than the latter (16 items versus 5 items).
However, conversely, the more items, the more compli-
cated and time-consuming is the measurement. Thus, an
appropriate measurement should be chosen depending
on the situation. As shown in Table 2, inter-relationships
between the changes in the OCD, mMRC, CRQ and
SGRQ were significant but modest, indicating that
changes in different measurements may reflect different
aspects of worsening of dyspnea.
Cross-sectionally, airflow limitation does not capture
the heterogeneity of COPD including dyspnea [27]. In
clinical trials assessing bronchodilator effects, improve-
ment in FEV1 was significantly correlated to reduction in
dyspnea [28,29]. However, no previous studies analyzed
factors contributory to the changes in dyspnea longitudin-
ally. We showed that, although cumulative correlations of
determination were low and many of these factors were
unknown, the change in FEV1 was significantly but
weakly (5-19%) correlated to the changes in dyspnea.
Similarly, reduction in DLCO was also weakly significantly
correlated to worsening of dyspnea (4-8%). Thus, as
COPD is characterized by dysfunction of small airways as
well as lung parenchyma [1], both may independently re-
flect progressive dyspnea. In contrast to the case of FEV1,
an annual increase in FRC (one measurement of statichyperinflation) was not significantly correlated with wor-
sening of daily dyspnea in this population. This is consist-
ent with our cross-sectional finding that, although both
airflow limitation and static hyperinflation contributed to
dyspnea in patients with COPD, the former was more
closely associated to dyspnea with activities of daily living
than the latter [30]. The changes in peak exercise mea-
surements were significantly correlated with the change
in dyspnea in some univariate analyses, but not in multi-
variate analyses except for the mMRC. Considering that,
in cross-sectional studies, mild correlations with airflow
limitation and moderate to strong correlations with exer-
cise capacity were expected [13], the relationships appear
to be the reverse in the longitudinal studies, and further
studies would be needed.
On the other hand, as compared to the physiological
measurements, worsening of psychological problems
such as anxiety and depression was more significantly
correlated to the worsening of dyspnea. Although psy-
chological problems are common in COPD [31] and
can greatly influence dyspnea, the longitudinal inter-
relationship between the two was observed in a sizable
proportion (14-17%). In addition, they impact future
risks of exacerbation or mortality [32,33]. Thus, it may
be beneficial to target this area, with a view to reduc-
tion of progressive dyspnea in COPD.
COPD is characterized by persistent airflow limita-
tion that is usually progressive [1]. However, recent
observational studies [20-22] indicated that the rate of
change in FEV1 is variable, and, that there are a num-
ber of patients who do not show decline of FEV1, who
are referred to as sustainers. A wide scatter was shown
in Figure 1 between the changes in dyspnea and the
changes in FEV1, and the changes in dyspnea were
considered to be as variable as in the changes in
FEV1. Furthermore, regarding regression lines, there
was a significant intercept shift in terms of deterior-
ation of mMRC, CRQ dyspnea and SGRQ activity, in-
dicating that these showed deterioration despite the
absence of changes in FEV1. Similarly, Mahler et al.
[3] reported that, while FEV1 did not increase or de-
crease over time, there was a small but significant de-
terioration in dyspnea over 2 years. Thus, disease
progression occurs through a worsening in dyspnea as
well as progressive airflow limitation. Clinicians should
pay attention to the change in dyspnea as well as lung
function, and, when it is observed, should consider
possible causes.
The present multiple regression analyses have indicated
that included variables were not sufficient to explain lon-
gitudinal changes in dyspnea. A limitation to this study
was that we did not assess important clinical features of
COPD such as exacerbations, comorbidities and systemic
inflammation. Exacerbations and comorbidities can affect
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status [34,35]. Therefore, consideration of problems crit-
ical from different angles for patients is important.
Peak Borg scores at the end of exercise were signifi-
cantly reduced. This finding may be related to the obser-
vation that patients tended to stop exercise earlier due
to exercise capacity deterioration as shown in peak exer-
cise physiological indices. Alternatively, patients tended
to stop exercise due rather to progressive leg fatigue
than to breathlessness: however, the fact that we did not
evaluate breathlessness and leg fatigue separately consti-
tutes a limitation. In addition, changes in Borg scores
were not significantly associated with any of the changes
in clinical measurements, including other dyspnea mea-
surements. In our previous studies, peak Borg scores at
the end of exercise were not associated with clinical
measurements cross-sectionally [13] or with mortality
[36], unlike dyspnea during activities of daily living.
Thus, the clinical significance of longitudinal changes in
peak dyspnea during exercise remains uncertain.
We included only male patients reflecting the fact that
COPD was much more common in males than females
in Japan at that time. However, recent studies have
reported that females showed a lower mortality rate but
greater incidence of dyspnea and poor health, and more
exacerbations [37,38]. Thus, there may be differences in
clinical course between males and females.
Conclusion
We have demonstrated that dyspnea during activities of
daily living worsened over time in patients with COPD.
As different dyspnea measurements showed different
evaluative properties, we should follow dyspnea using
appropriate measurements. Namely, multidimensional
dyspnea measurements such as the TDI or UCSD Short-
ness of Breath Questionnaire [39], or dyspnea dimension
of health status questionnaires such as the CRQ would
be expected to be better than unidimensional measure-
ments such as the OCD or MRC, although further stud-
ies are needed. Progressive dyspnea was related to not
only progressive airflow limitation but also to various
factors such as worsening of diffusing capacity or psy-
chological status.
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